References
- Group F-NBW . BEST (Biomarkers, EndpointS, and other Tools) resource. US FDA; FDA-NIH Biomarker Working Group, Silver Spring, MD ; Copublished by NIH (US), Bethesda, MD. www.ncbi.nlm.nih.gov/books/NBK338449/.
- Arnold ME , BoothB, KingL, RayC. Workshop report: crystal city vi-bioanalytical method validation for biomarkers. AAPS J. doi: 10.1208/s12248-016-9946-6 (2016) ( Epub ahead of print).
- Lee JW , DevanarayanV, BarrettYCet al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23 (2), 312–328 (2006).
- Amaravadi L , SongA, MylerHet al. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3 – LBA, biomarkers and immunogenicity). Bioanalysis7 (24), 3107–3124 (2015).
- Cummings J , WardTH, DiveC. Fit-for-purpose biomarker method validation in anticancer drug development. Drug Discov. Today15 (19–20), 816–825 (2010).
- Jani D , AllinsonJ, BerishaFet al. Recommendations for use and fit-for-purpose validation of biomarker multiplex ligand binding assays in drug development. AAPS J. 18 (1), 1–14 (2016).
- Khan MU , BowsherRR, CameronMet al. Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development. Bioanalysis7 (2), 229–242 (2015).
- Lee JW , HallM. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877 (13), 1259–1271 (2009).
- Aldo P , MarusovG, SvancaraD, DavidJ, MorG. Simple Plex(™): a novel multi-analyte, automated microfluidic immunoassay platform for the detection of human and mouse cytokines and chemokines. Am. J. Reprod. Immunol. 75 (6), 678–693 (2016).
- Hennig C , RinkL, FaginU, JabsWJ, KirchnerH. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J. Immunol. Methods. 235 (1–2), 71–80 (2000).
- Deforge LE , LoyetKM, DelarosaDet al. Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF. J. Immunol. Methods362 (1–2), 70–81 (2010).
- Bartels EM , Ribel-MadsenS. Cytokine measurements and possible interference from heterophilic antibodies--problems and solutions experienced with rheumatoid factor. Methods61 (1), 18–22 (2013).
- Churchman SM , GeilerJ, ParmarRet al. Multiplexing immunoassays for cytokine detection in the serum of patients with rheumatoid arthritis: lack of sensitivity and interference by rheumatoid factor. Clin. Exp. Rheumatol. 30 (4), 534–542 (2012).
- Baird CL , TanR, FischerCJ, VictryKD, ZangarRC, RodlandKD. Reducing heterophilic antibody interference in immunoassays using single-chain antibodies. Anal. Biochem. 419 (2), 333–335 (2011).
- De Jager W , PrakkenBJ, BijlsmaJW, KuisW, RijkersGT. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J. Immunol. Methods300 (1–2), 124–135 (2005).
- Yeung D , CiottiS, PurushothamaSet al. Evaluation of highly sensitive immunoassay technologies for quantitative measurements of sub-pg/ml levels of cytokines in human serum. J. Immunol. Methods437, 53–63 (2016).